These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28472350)

  • 41. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
    Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
    Guerrero F; Arnaud C; Nguyen F; Boneu B; Sié P
    Thromb Haemost; 2006 Apr; 95(4):728-34. PubMed ID: 16601846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiplex PCR for one-step determination of the G20210A variation and the factor V Leiden mutation by denaturing gradient gel electrophoresis (DGGE).
    Patri S; Salmeron S; Caillon M; Kitzis A; Chomel JC
    Thromb Haemost; 1999 Feb; 81(2):313-4. PubMed ID: 10064013
    [No Abstract]   [Full Text] [Related]  

  • 44. Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
    Gessoni G; Valverde S; Valle L; Gessoni F; Caruso P; Valle R
    Int J Lab Hematol; 2017 Aug; 39(4):418-422. PubMed ID: 28318106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
    Tosetto A; Castaman G; Cappellari A; Rodeghiero F
    Thromb Haemost; 2000 Nov; 84(5):811-4. PubMed ID: 11127861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
    Marchiori A; Mosena L; Prins MH; Prandoni P
    Haematologica; 2007 Aug; 92(8):1107-14. PubMed ID: 17650440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease.
    Haslam N; Standen GR; Probert CS
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1289-91. PubMed ID: 10563542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis and management of factor V Leiden.
    Campello E; Spiezia L; Simioni P
    Expert Rev Hematol; 2016 Dec; 9(12):1139-1149. PubMed ID: 27797270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.
    Schouten M; van't Veer C; Roelofs JJ; Levi M; van der Poll T
    Crit Care; 2010; 14(4):R145. PubMed ID: 20682036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke.
    Duran R; Biner B; Demir M; Celtik C; Karasalihoğlu S
    Clin Appl Thromb Hemost; 2005 Jan; 11(1):83-8. PubMed ID: 15678277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance.
    Moore GW; Chege E; Culhane AP; Hunt BJ
    Int J Lab Hematol; 2015 Dec; 37(6):844-52. PubMed ID: 26303324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.
    Wu O; Robertson L; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Langhorne P; Brenkel I; Regan L; Greer I
    Health Technol Assess; 2006 Apr; 10(11):1-110. PubMed ID: 16595080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factor V Leiden with deep venous thrombosis.
    Gardner J
    Clin Lab Sci; 2003; 16(1):6-9. PubMed ID: 12587652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Retinal artery occlusion and anterior ischemic optic neuropathy associated with factor V Leiden mutation: A case report].
    Elleuch IE; Sayadi S; Rahali N; Dridi T; Zbiba W
    J Fr Ophtalmol; 2020 Apr; 43(4):294-297. PubMed ID: 32107025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factor V Leiden detection by polymerase chain reaction-restriction fragment length polymorphism with mutagenic primers in a multiplex reaction with Pro G20210A--a novel technique.
    Welbourn JT; Maiti S; Paley J
    Hematology; 2003 Apr; 8(2):73-5. PubMed ID: 12745655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE registry.
    Gabriel F; Portolés O; Labiós M; Rodríguez C; Cisneros E; Vela J; Nuñez M;
    Clin Appl Thromb Hemost; 2013; 19(1):42-7. PubMed ID: 22327823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
    Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intraindividual consistency of the activated protein C resistance phenotype.
    Tosetto A; Simioni M; Madeo D; Rodeghiero F
    Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.